Non-Drug Costs of CAR-T Cell Therapy May Exceed $50,000
Researchers noted that while non-drug costs account for only 7% of CAR-T therapy-related expenses, these costs may range from $30,000 to $56,000.
All articles by Jonathan Goodman, MPhil
Lenalidomide: Feasible for Patients With Relapsed, Refractory MCL
At time of analysis, 14 of the 22 complete responses were ongoing.
Tazemetostat Active in Non-Hodgkin Lymphomas, Solid Tumors
The recommended phase 2 dose is 800 mg twice daily.
FDA Grants Priority Review to Duvelisib for CLL/SLL and Follicular Lymphoma
The FDA is reviewing a New Drug Application, which is requesting full approval for CLL/SLL and accelerated approval for follicular lymphoma.
FDA Approves Nilotinib for Pediatric Patients With CML
Patients one year or older are now eligible to receive the drug.
Novel STAT3 Inhibitor Shows Some Anticancer Activity
Eighteen and 127 patients were enrolled into dose-escalation and dose expansion cohorts, respectively.
Pacritinib May Benefit Some Patients With Myelofibrosis
Researchers evaluated whether pacritinib would improve SVR and TSS compared with the best available therapy, including ruxolitinib.
Cognitive Impairment Worsens Survival Among Elderly Patients With Hematologic Cancer
A variety of cognitive impairments are common in the elderly US population, with as many as 14% of individuals over 70 being affected by dementia.
Umbralisib: A Promising Therapy for Hematologic Malignancies
Umbralisib has shown improved isoform selectivity over currently used PI3Kδ inhibitors.
Patients With CLL With High Cancer-Specific Stress May Benefit From Psychological Intervention
The impact of cancer-specific stress on psychological and physical functioning among patients with CLL was not previously well-understood.
Next post in Leukemia
